Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the ...

Japanese ophthalmology company Santen Pharmaceutical (TYO: 4536) announced that it will launch Ryjusea Mini solution 0.025% ...

The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

Glenmark Pharmaceuticals Ltd on Thursday (March 20) said its arms Pharmaceuticals Inc., USA, has received final approval from ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), ...

Glenmark Pharmaceuticals rose 1.95% to Rs 1,506.95 after its US subsidiary, Glenmark Pharmaceuticals Inc., USA, received approval from the US Food & Drug Administration (USFDA) for its Olopatadine ...

Advancements in medical imaging and computational methodologies have significantly transformed the field of ophthalmology, allowing for unmatched precision ...

China's ophthalmic laser market is projected to grow at a CAGR of about 4% through 2033, driven by advancements in laser ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

The country accounted for 25% of the Asia-Pacific market in 2024. China’s ophthalmic laser market is projected to expand at a ...